Local biotech company staying put

I have written a fair number of pieces in my time on Amarillo Biosciences, a biotechnology firm that develops drug therapies for various illnesses.
My most recent news concerned them striking an incentive deal with Junction City, Kan. to relocate there.
Turns out, the deal, which could have netted the company as much as $5 million, fell through.
Amarillo Biosciences is developing Interferon, an antiviral protein naturally produced in the body. The drug has shown promise in treating oral warts in HIV-positive patients, chronic cough, the flu, and Hepatitis B and C.
I’ve been trying for more than a month to get a hold of the company’s chief executive and founder, Dr. Joe Cummins, to talk about their next move now that the one in Kansas is dead. No matter how many voice mails I leave or the number of e-mails I send, I only receive short e-mailed replies saying Cummins is traveling and too busy to talk.
The most recent e-mail he sent read: “I spent 3 weeks in San Antonio and must fly to Omaha for 3 weeks tomorrow. We remain in limbo on relocation. Joe”
Amarillo Bioscience’s contract with Junction City had been approved by all the necessary boards in Kansas. However, Amarillo Biosciences requested changes that negated the contract nearly two months after Junction City approved it, said Jeffrey Black, executive director of Economic Development for Junction City.
Now the company, searching for money in a tough economy, is seeking another deal elsewhere.
As the national economy has tanked, money available for research dried up, and brokering incentives to move is a good way to raise money.
I need to interview Cummins before a story is printed. However, I will keep trying to get him.